Announced Wed, 15 Apr · 13:00 IST

<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+6.5%1-day move
₹56.29
prior close
₹60.99
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.0-2.0-2.0-2.0+6.5+5.4-0.5-0.5-0.5+20.8+6.6+61.6+108.9+67.8
Up moveDown movePending
AI summary

Aspira Pathlab & Diagnostics Limited has filed an annual disclosure with BSE confirming that it does not qualify as a 'Large Corporate' (LC) under SEBI guidelines. The company states that the mandatory annual disclosure requirement per SEBI circular dated November 26, 2018 is not applicable to it for financial year 2025-26. This is a routine compliance filing where the company is clarifying its non-applicability status rather than reporting actual fundraising data.

Likely market impact

No direct impact on shareholders or stock price. This filing merely confirms the company is below the threshold that would trigger mandatory debt fundraise disclosures, indicating smaller-scale operations relative to SEBI's Large Corporate criteria.